Procurement of DAROLUTAMIDE TABLETS (NUBEQA) 300mg

GoodsAward procedure without prior publication of a call for competition

Awarded value£140,000published contract · exc. VAT

Awarded 7 Apr 2023no call for competition

Awarded to Bayer Plc

Notice summaryFrom the published notice

Procurement of DAROLUTAMIDE TABLETS (NUBEQA) 300mg - Patent Protected Medicine.

What is being bought

Published requirement description

Procurement of DAROLUTAMIDE TABLETS (NUBEQA) 300mg - Patent Protected Medicine

CPV: Medical equipments, pharmaceuticals and personal care products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland · Belfast Health and Social Care Trust

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £140,0001 contract exc. VAT

Bids received 1

Contracts signed 1latest 7 Apr 2023

Awarded to	Value	Date	Status
Bayer Plc	£140,000 †	—	Awarded

Contracts

PROCUREMENT OF DAROLUTAMIDE TABLETS (NUBEQA) 300mg · Bayer Plc
Signed
7 Apr 2023
Value
£140,000
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 18 Apr 2023, 12:46 BST
Last source update: 18 Apr 2023, 12:46 BST
Authority reference: DACPM2022-92
FTS notice number: 2023/S 000-011082
Classification (CPV): Medical equipments, pharmaceuticals and personal care products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-03bf70 Find a Tender

Why no open competition: The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
Published justification: These are branded patent protected medicines that are essential to patient care and are available from only one economic operator. The absence of competition is not a result of the artificial narrowing of the parameters of the procurement.

Contracting authorityNHS & healthcareBody governed by public lawHealth LISBURN ROAD, BELFAST, Northern Ireland, BT97ABContact name, email

1 commercial party on the notice

Bayer PlcAwarded supplierGB-COH: 00935048 400 South Oak Way, Green Park,, Reading, South East, RG2 6AD

Official links; attachments are not copied

No document links were published on the notice.